InMed Pharmaceuticals Inc. (INM)
2025-03-31 | 2024-09-30 | |||
|---|---|---|---|---|
| Revenues | - | 1,264,638 | ||
| Cost of revenue | - | 771,225 | ||
| Gross profit | - | 493,413 | ||
| Research and development expense | - | 771,180 | ||
| General and administrative expense | - | 1,421,926 | ||
| Unrealized gain (loss), foreign currency transaction, before tax | - | 19,310 | ||
| Depreciation, depletion and amortization, nonproduction | - | 54,579 | ||
| Total operating expenses | - | 2,228,375 | ||
| Investment income, interest | - | 57,094 | ||
| Loss before income taxes | - | -1,677,868 | ||
| Net loss | - | -1,677,868 | ||
| Basic eps | -1.94 | -2.71 | ||
| Diluted eps | -1.94 | -2.71 | ||
| Basic average shares | 1,095,973 | 620,127 | ||
| Diluted average shares | 1,095,973 | 620,127 | ||